The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.
 
Ye Guo
Honoraria - BMS; Merck Serono; MSD; Roche
Consulting or Advisory Role - Bayer; Merck Serono; MSD; Roche
 
Chunwang Yuan
No Relationships to Disclose
 
Weimin Ding
No Relationships to Disclose
 
Yi Gao
No Relationships to Disclose
 
Xu Zhu
No Relationships to Disclose
 
Jieer Ying
No Relationships to Disclose
 
Meili Sun
Speakers' Bureau - TopAlliance BioSciences Inc
 
Jingdong Zhang
No Relationships to Disclose
 
Zhixiang Zhuang
No Relationships to Disclose
 
Yangqing Huang
No Relationships to Disclose
 
Lichun Deng
No Relationships to Disclose
 
Ping Chen
No Relationships to Disclose
 
Yuxian Bai
No Relationships to Disclose
 
Zuoxing Niu
No Relationships to Disclose
 
Wei Li
No Relationships to Disclose
 
Xiaoyu Yin
No Relationships to Disclose
 
Aibing Xu
No Relationships to Disclose
 
Yufeng Cheng
No Relationships to Disclose
 
Jin Li
No Relationships to Disclose